pharmaphorum December 6, 2018
Pharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting review by the FDA, according to a new report from US trade body PhRMA.
The first ever Medicines in Development report on cell and gene therapies found that there are 289 novel gene and cell therapies in development or awaiting review, and 111 of these are aimed at cancer.
More than 100 diseases are being studied for potential treatment with cell and gene therapies, including Alzheimer’s disease, cardiovascular disease, neurological disorders, eye disorders, and infectious diseases.
The report follows several landmark developments in the field over the last year and a half, starting with the FDA’s first approval of Novartis’ cancer cell...
Today's Sponsors
Today's Sponsor